Biohaven trashes troriluzole in OCD after asset bungles phase 3 trial
12th August 2025 Uncategorised 0More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee to consider the asset’s potential approval in a rare disease, pushing the PDUFA date to the fourth quarter, troriluzole has now failed a phase 3 trial in obsessive-compulsive disorder.
More: Biohaven trashes troriluzole in OCD after asset bungles phase 3 trial
Source: fierce